Paradigm Biopharmaceuticals (ASX:PAR) has reached an important scientific milestone with the peer-reviewed publication of results from its Phase 2 biomarker study investigating injectable pentosan polysulfate sodium (iPPS) in patients with moderate to severe knee osteoarthritis. …
Peer-reviewed validation strengthens Paradigm’s osteoarthritis program
January 28, 2026 Australian Biotech
Latest Video
Georgia Forrest
New Stories
-
Peer-reviewed validation strengthens Paradigm’s osteoarthritis program
January 28, 2026 - - Australian Biotech -
Patrys completes Reliis acquisition, expands clinical pipeline and strengthens board
January 28, 2026 - - Australian Biotech -
UK life sciences report highlights pressures familiar to Australian industry
January 27, 2026 - - Latest News -
Americans pay a much lower share of health costs than we do in Australia
January 27, 2026 - - Latest News -
Australia’s health information ecosystem is very full, but do the best voices dominate?
January 27, 2026 - - Latest News -
Strong US debut for Novo Nordisk pill signals potential shift in global weight loss market
January 26, 2026 - - Latest News -
Leading pharmacists honoured in 2026 Australia Day Awards
January 26, 2026 - - Latest News